Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet Lond Engl. 2020;395:1146–62.

Article  CAS  Google Scholar 

Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell Lymphoblastic Leukemia. N. Engl J Med. 2018;378:439–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31–42.

Article  CAS  PubMed  Google Scholar 

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.

Article  CAS  PubMed  Google Scholar 

Abramson, Palomba JS, Gordon LI ML, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52.

Article  PubMed  Google Scholar 

Zhu F, Wei G, Zhang M, Zhao H, Wu W, Yang L, et al. Factors associated with costs in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory B-cell malignancies. Cell Transpl. 2020;29:963689720919434.

Article  Google Scholar 

Erdoğan E, Yalçın K, Hemşinlioğlu C, Sezgin A, Seyis U, Kançağı DD, et al. Preliminary report of the academic CAR-T (ISIKOK-19) cell clinical trial in Turkey: characterization of product and outcomes of clinical application. Turk J Haematol J Turk Soc Haematol. 2022;39:206–10.

Google Scholar 

Ortíz-Maldonado V, Rives S, Castellà M, Alonso-Saladrigues A, Benítez-Ribas D, Caballero-Baños M, et al. CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed/refractory malignancies. Mol Ther J Am Soc Gene Ther. 2021;29:636–44.

Article  Google Scholar 

Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2020;26:26–33.

Article  CAS  Google Scholar 

Chen G, Herr M, Nowak J, Ho C, Almyroudis N, Attwood K, et al. Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. Haematologica. 2023;108:615–20.

Article  PubMed  Google Scholar 

Buechner J, Grupp SA, Hiramatsu H, Teachey DT, Rives S, Laetsch TW, et al. Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Adv. 2021;5:593–601.

Article  CAS  PubMed  PubMed Central  Google Scholar